LDLR and metabolic syndrome: In addition, CRISPR/Cas9-mediated knockouts of LDLR and LDLR/APOE double-knockout in rabbits successfully demonstrated reduced high-density lipoprotein (HDL) cholesterol levels, severe dyslipidemia and atherosclerotic lesions in the rabbits aorta [143,150].